<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Iloprost: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Iloprost: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Iloprost: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11540" href="/d/html/11540.html" rel="external">see "Iloprost: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="120072" href="/d/html/120072.html" rel="external">see "Iloprost: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F181868"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ventavis</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F181883"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Prostacyclin;</li>
<li>
                        Prostaglandin;</li>
<li>
                        Vasodilator</li></ul></div>
<div class="block doa drugH1Div" id="F181870"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58a3cd23-4fbc-4ca7-8c74-26fd785e3679">Acute vasodilator testing in patients with pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute vasodilator testing in patients with pulmonary arterial hypertension (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Acute vasodilator testing is recommended in patients with idiopathic, heritable, or drug-induced pulmonary arterial hypertension to assess eligibility for treatment with a calcium channel blocker (eg, ER nifedipine) (ACCF/AHA [McLaughlin 2009]; ESC/ERS [Humbert 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Inhalation</b>: 5 to 10 mcg delivered over 10 to 15 minutes (ESC/ERS [Humbert 2022]; Hernández-Oropeza 2018; Jing 2009).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b6777ad-1508-4cf7-924a-99d10f0a73e1">Pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult a pulmonary arterial hypertension specialist for all management decisions; choice of therapy is dependent on etiology, risk stratification, cardiopulmonary comorbidities, and response to other agents. Prostacyclin analogues are generally reserved for initial therapy in high-risk patients or used as adjunctive therapy in patients who continue to deteriorate on oral agents (ACCP [Klinger 2019]; ESC/ERS [Humbert 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Inhalation:</b> Initial: 2.5 mcg/dose; if tolerated, increase to 5 mcg/dose. Administer each dose 6 to 9 times per day (dosing at intervals ≥2 hours while awake according to individual need and tolerability). Maintenance dose: 2.5 to 5 mcg/dose; maximum total daily dose: 45 mcg (ie, 5 mcg/dose 9 times daily).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991235"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988476"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F181871"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812521"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="120072" href="/d/html/120072.html" rel="external">see "Iloprost: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Avoid abrupt withdrawal or sudden large dose reductions when discontinuing therapy to prevent rebound pulmonary hypertension.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b6777ad-1508-4cf7-924a-99d10f0a73e1">Pulmonary arterial hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension (PAH):</b> Limited data available: Infants, Children, and Adolescents: Inhalation: Initial: 2.5 mcg/dose; if initial dose is tolerated, titrate up to 5 mcg/dose; lower initial doses (ie, 1.25 mcg/dose) have been recommended for infants and small children by some experts. Administer 6 to 9 times daily with dosing intervals of every 2 to 3 hours while awake (AHA/ATS [Abman 2015]; Hansmann 2016); highest reported daily dose: 100 mcg/<b>day </b>(Mulligan 2012); usual adult maximum daily dose: 45 mcg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ee182d1-5737-4a68-903e-8f2184ae4f36">Pulmonary hypertensive crisis, postoperative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary hypertensive crisis, postoperative:</b> Very limited data available: <b>Note:</b> Efficacy may be impacted by drug delivery system (eg, type of nebulizer, placement in ventilator circuit, mode of ventilation) (DiBlasi 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Inhalation: Initial: 0.5 mcg/kg over 10 minutes; if no response seen, increase to 1 mcg/kg over 10 minutes and then to a maximum dose of 2 mcg/kg over 10 minutes; administer doses every 30 minutes up to 5 doses; dosing based on a prospective open label study that evaluated 8 pediatric patients (age range: 1 month to 13 years) who developed pulmonary hypertensive crisis following repair of congenital heart defects; all patients responded to iloprost as evidenced by a significant decrease in their mean arterial pressure and increase in oxygen saturation and were weaned off ventilation and discharged home. No adverse effects were observed (Limsuwan 2008).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52175133"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, no adjustment is required in patients with renal impairment who are not on dialysis (the effect of dialysis on iloprost exposure is unknown).</p></div>
<div class="block dohp drugH1Div" id="F52175134"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment may be considered in patients with moderate to severe impairment.</p></div>
<div class="block adr drugH1Div" id="F181846"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (27%), hypotension (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (30%), trismus (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Jaw pain (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (39%), flu-like symptoms (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Syncope (8%), palpitations (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Insomnia (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (7%), glossalgia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (7%), muscle cramps (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hemoptysis (5%), pneumonia (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Bronchospasm, cardiac failure, chest pain, dizziness, dyspnea, dysgeusia, epistaxis, hypersensitivity reaction, mouth irritation, paradoxical reaction (increased post-void residual urine volume), renal failure, skin rash, supraventricular tachycardia, thrombocytopenia, tongue irritation, wheezing</p></div>
<div class="block coi drugH1Div" id="F181858"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F181844"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Pulmonary edema: If pulmonary edema occurs during administration, discontinue therapy immediately; may be a sign of pulmonary venous hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Rebound pulmonary hypertension: Abrupt withdrawal/large dosage reductions may worsen symptoms of PAH. Immediate access to medication and back-up inhalation device is essential to prevent treatment interruptions.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Syncope:  Hypotension leading to syncope has been observed. Dosage or therapy adjustment may be required if exertional syncope occurs. Use caution with concurrent conditions or medications that may increase risk of syncope.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Bleeding disorders: Use with caution in patients with active bleeding or at increased risk of bleeding (eg, concomitant anticoagulation); mild inhibitor of platelet aggregation when administered as an aerosol. </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hypotension: Do not use in patients with hypotension (systolic BP &lt;85 mm Hg).</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Respiratory disease:  Safety and efficacy have not been established in patients with other concurrent pulmonary diseases (eg, COPD, severe asthma, or acute pulmonary infections); may induce bronchospasm in patients with hyper-reactive airways. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Administration: Intended for inhalation administration using only the I-neb AAD System. Solution should not come in contact with skin or eyes. Monitor vital signs during initiation. </p></div>
<div class="block foc drugH1Div" id="F181853"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Inhalation [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ventavis: 10 mcg/mL (1 mL); 20 mcg/mL (1 mL) [contains alcohol, usp, tromethamine]</p></div>
<div class="block geq drugH1Div" id="F181842"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323193"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ventavis Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mcg/mL (per mL): $169.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mcg/mL (per mL): $169.72</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F181855"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Inhalation:</b> Immediate access to medication and a back-up inhalation device is essential to prevent treatment interruptions. Do not mix with other medications. For inhalation use only via the I-neb AAD System. Refer to the I-neb AAD System instructions for adding ampul contents to the medication chamber. The 20 mcg/mL concentration is intended for patients who are maintained at the 5 mcg dose and who have repeatedly experienced extended treatment times. After use, discard any solution remaining in I-neb AAD medication chamber and do not reuse, then clean the system. Do not orally ingest solution.</p></div>
<div class="block admp drugH1Div" id="F52613029"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Inhalation: Immediate access to medication and a back-up inhalation device is essential to prevent treatment interruptions. Do not mix with other medications. Per the manufacturer, iloprost is for inhalation only via the I-neb AAD System. Refer to the I-neb AAD System instructions for adding ampule contents to the medication chamber. The 20 mcg/mL concentration is intended for patients who are maintained at the 5 mcg dose and who have repeatedly experienced extended treatment times. After use, discard remainder of the medicine; not for reuse. In neonatal patients, dilution of doses in 1 mL of NS has been reported (Kahveci 2014). Efficacy may be impacted by drug delivery system (eg, type of nebulizer, placement in ventilator circuit, mode of ventilation) (DiBlasi 2016).</p></div>
<div class="block use drugH1Div" id="F181854"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Pulmonary arterial hypertension: </b>Treatment of pulmonary arterial hypertension (World Health Organization group I) in patients with New York Heart Association functional class III or IV symptoms to improve exercise tolerance, symptoms, and diminish clinical deterioration.</p></div>
<div class="block off-label drugH1Div" id="F51284801"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute vasodilator testing in pulmonary arterial hypertension</p></div>
<div class="block cyt drugH1Div" id="F13299509"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F181848"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Prostacyclin Analogues may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Prostacyclin Analogues may enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Prostacyclin Analogues may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F181860"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information related to the use of iloprost in pregnancy is limited (Elliot 2005; Horng 2016; Zhang 2018). Women with pulmonary arterial hypertension are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014).</p></div>
<div class="block brc drugH1Div" id="F20624534"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if iloprost is excreted in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F181851"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate, blood pressure, respiratory rate and adverse effects (eg, flushing, headache, nausea) at baseline and with dosage adjustment. Monitor for improvements in pulmonary function, decreased exertional dyspnea, fatigue, syncope and chest pain, and quality of life.</p></div>
<div class="block pha drugH1Div" id="F181843"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Acutely, iloprost dilates systemic and pulmonary arterial vascular beds. With longer-term use, alters pulmonary vascular resistance and suppresses vascular smooth muscle proliferation. In addition, it is a mild endogenous inhibitor of platelet aggregation when aerosolized (Beghetti 2002).</p></div>
<div class="block phk drugH1Div" id="F181857"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: 30 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: IV: 0.7 to 0.8 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~60%, primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via beta oxidation of the carboxyl side chain; main metabolite, tetranor-iloprost (inactive in animal studies)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 20 to 30 minutes (effect), 7 to 9 minutes (elimination)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Within 5 minutes after inhalation</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (68% as metabolite); feces (12%)</p></div>
<div class="block phksp drugH1Div" id="F51159827"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Inhaled iloprost has not been evaluated in subjects with impaired renal function. In a study with IV infusion of iloprost in patients with ESRD requiring intermittent dialysis treatment, the mean AUC<sub>0-4h</sub> was 230 pg•h/mL compared with 54 pg•h/mL in patients with renal failure not requiring intermittent dialysis, and 48 pg•h/mL in healthy patients. The half-life was similar in both groups.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Inhaled iloprost has not been evaluated in subjects with impaired hepatic function. In an IV iloprost study in patients with liver cirrhosis, the mean Cl in Child-Pugh class B subjects was approximately 10 mL/min/kg (half that of healthy patients). Following oral administration, the mean AUC<sub>0-8h</sub> in Child-Pugh class B patients was 1,725 pg•h/mL compared with 117 pg•h/mL in healthy subjects receiving the same oral iloprost dose. In Child-Pugh class A subjects, the mean AUC<sub>0-8h</sub> was 639 pg•h/mL. Although exposure increased with hepatic impairment, there was no effect on half-life.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F181861"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Iloprost dosa</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Ventavis</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Ventavis</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Ventavis</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Iloprost ibisqus | Iloprost ratiopharm | Iloprost Zentiva | Ventavis</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Ilopera | Ventavis</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Iloprost Zentiva</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Ventavis</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ilomedine | Iloprost teva | Ventavis</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Iloprost | Ventavis</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Ventavis</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Endoprost | Ilomedin | Iloprost | Iloprost Zentiva | Ventavis</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Ventavis</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ilomedine | Iloprost | Ventavis</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Ventavis</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow iloprost | Ilomedin | Iloprost | Vebulis | Ventavis</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Iloprost pharmamentum | Ventavis</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Ventavis</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Ventavis</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Ventavis</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ventavis</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin | Ventavis</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ilomedine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Divodin | Ilomedin | Ilopera | Ilotemol | Vebulis | Ventavis</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ilomedin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26534956">
<a name="26534956"></a>Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society [published correction appears in <i>Circulation</i>. 2016;133(4):e368]. <i>Circulation</i>. 2015;132(21):2037-2099.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/26534956/pubmed" id="26534956" target="_blank">26534956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11936532">
<a name="11936532"></a>Beghetti M, Reber G, de Moerloose P, et al, “Aerosolized Iloprost Induces a Mild but Sustained Inhibition of Platelet Aggregation,” <i>Eur Respir J</i>, 2002, 19(3):518-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/11936532/pubmed" id="11936532" target="_blank">11936532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27162615">
<a name="27162615"></a>DiBlasi RM, Crotwell DN, Shen S, Zheng J, Fink JB, Yung D. Iloprost drug delivery during infant conventional and high-frequency oscillatory ventilation. <i>Pulm Circ</i>. 2016;6(1):63-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/27162615/pubmed" id="27162615" target="_blank">27162615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14694957">
<a name="14694957"></a>Ehlen M, Wiebe B. Iloprost in persistent pulmonary hypertension of the newborn. <i>Cardiol Young</i>. 2003;13(4):361-363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/14694957/pubmed" id="14694957" target="_blank">14694957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17710738">
<a name="17710738"></a>Eifinger F, Sreeram N, Mehler K, Huenseler C, Kribs A, Roth B. Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study. <i>Klin Padiatr</i>. 2008;220(2):66-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/17710738/pubmed" id="17710738" target="_blank">17710738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15994404">
<a name="15994404"></a>Elliot CA, Stewart P, Webster VJ, et al. The use of iloprost in early pregnancy in patients with pulmonary arterial hypertension. <i>Eur Respir J</i>. 2005;26(1):168-173. doi: 10.1183/09031936.05.00128504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/15994404/pubmed" id="15994404" target="_blank">15994404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14676265">
<a name="14676265"></a>Emmel M, Keuth B, and Schickendantz S, “Paradoxical Increase of Pulmonary Vascular Resistance During Testing of Inhaled Iloprost,” <i>Heart</i>, 2004, 90(1):e2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/14676265/pubmed" id="14676265" target="_blank">14676265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22755287">
<a name="22755287"></a>Gokce I, Kahveci H, Turkyilmaz Z, Adakli B, Zeybek C. Inhaled iloprost in the treatment of pulmonary hypertension in very low birth weight infants: a report of two cases. <i>J Pak Med Assoc</i>. 2012;62(4):388-391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/22755287/pubmed" id="22755287" target="_blank">22755287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27053700">
<a name="27053700"></a>Hansmann G, Apitz C. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. <i>Heart</i>. 2016;102 Suppl 2:ii67-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/27053700/pubmed" id="27053700" target="_blank">27053700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29718009">
<a name="29718009"></a>Hernández-Oropeza JL, Rodríguez-Reyna TS, Carrillo-Pérez DL, et al. Pulmonary vasoreactivity and phenotypes in pulmonary arterial hypertension associated to connective tissue diseases. <i>Rev Invest Clin</i>. 2018;70(2):82-87. doi:10.24875/RIC.18002437<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/29718009/pubmed" id="29718009" target="_blank">29718009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27341074">
<a name="27341074"></a>Horng M, Mohammad I, Smith ZR, Awdish RL, Cajigas HR. Inhaled Iloprost for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) During Pregnancy: A Case Report. <i>Pharmacotherapy</i>. 2016;36(9):e142-e147. doi: 10.1002/phar.1793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/27341074/pubmed" id="27341074" target="_blank">27341074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017548">
<a name="36017548"></a>Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.<i> Eur Heart J</i>. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/36017548/pubmed" id="36017548" target="_blank">36017548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15459304">
<a name="15459304"></a>Humbert M, Sitbon O, and Simmoneau G, “Treatment of Pulmonary Arterial Hypertension,” <i>N Engl J Med</i>, 2004, 351(14):1425-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/15459304/pubmed" id="15459304" target="_blank">15459304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19213781">
<a name="19213781"></a>Jing ZC, Jiang X, Han ZY, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. <i>Eur Respir J</i>. 2009;33(6):1354-1360. doi:10.1183/09031936.00169608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/19213781/pubmed" id="19213781" target="_blank">19213781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420987">
<a name="24420987"></a>Kahveci H, Yilmaz O, Avsar UZ, et al. Oral sildenafil and inhaled iloprost in the treatment of pulmonary hypertension of the newborn. <i>Pediatr Pulmonol</i>. 2014;49(12):1205-1213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/24420987/pubmed" id="24420987" target="_blank">24420987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30660783">
<a name="30660783"></a>Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. <i>Chest</i>. 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/30660783/pubmed" id="30660783" target="_blank">30660783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18096256">
<a name="18096256"></a>Limsuwan A, Wanitkul S, Khosithset A, Attanavanich S, Samankatiwat P. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. <i>Int J Cardiol</i>. 2008;129(3):333-338.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/18096256/pubmed" id="18096256" target="_blank">18096256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19389575">
<a name="19389575"></a>McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. <i>J Am Coll Cardiol</i>. 2009;53(17):1573-1619. doi:10.1016/j.jacc.2009.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/19389575/pubmed" id="19389575" target="_blank">19389575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21926655">
<a name="21926655"></a>Mulligan C, Beghetti M. Inhaled iloprost for the control of acute pulmonary hypertension in children: a systematic review. <i>Pediatr Crit Care Med</i>. 2012;13(4):472-480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/21926655/pubmed" id="21926655" target="_blank">21926655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20153158">
<a name="20153158"></a>Olschewski H, Hoeper MM, Behr J, et al, "Long-Term Therapy With Inhaled Iloprost in Patients With Pulmonary Hypertension," <i>Respir Med</i>, 2010, 104(5):731-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/20153158/pubmed" id="20153158" target="_blank">20153158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14555558">
<a name="14555558"></a>Olschewski H, Rohde B, Behr J, et al, “Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension,” <i>Chest</i>, 2003, 124(4):1294-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/14555558/pubmed" id="14555558" target="_blank">14555558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12151469">
<a name="12151469"></a>Olschewski H, Simonneau G, Galie N, et al, “Inhaled Iloprost for Severe Pulmonary Hypertension,” <i>N Engl J Med</i>, 2002, 347(5):322-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/12151469/pubmed" id="12151469" target="_blank">12151469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25842794">
<a name="25842794"></a>Sompradeekul S, Wattanasiriphakdee S. Hemodynamic effect of iloprost inhalation and oral sildenafil during acute vasoreactivity test in pulmonary arterial hypertension. <i>J Med Assoc Thai</i>. 2015;98(2):144-149.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/25842794/pubmed" id="25842794" target="_blank">25842794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24937180">
<a name="24937180"></a>Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. <i>Chest</i>. 2014;146(2):449-475. doi: 10.1378/chest.14-0793.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/24937180/pubmed" id="24937180" target="_blank">24937180</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ventavis (iloprost) [prescribing information]. Titusville, NJ: Actelion Pharmaceuticals US Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23797963">
<a name="23797963"></a>Yilmaz O, Kahveci H, Zeybek C, Ciftel M, Kilic O. Inhaled iloprost in preterm infants with severe respiratory distress syndrome and pulmonary hypertension. <i>Am J Perinatol</i>. 2014;31(4):321-326.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/23797963/pubmed" id="23797963" target="_blank">23797963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29525197">
<a name="29525197"></a>Zhang J, Lu J, Zhou X, et al. Perioperative management of pregnant women with idiopathic pulmonary arterial hypertension: an observational case series study from China. <i>J Cardiothorac Vasc Anesth</i>. 2018;32(6):2547-2559. doi: 10.1053/j.jvca.2018.01.043.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/iloprost-drug-information/abstract-text/29525197/pubmed" id="29525197" target="_blank">29525197</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8895 Version 187.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
